A key factor in the success of a developing drug or therapy is the success of early clinical trials. A focus on Good Manufacturing Practice (GMP) standards for phase 1, first-in-human trials is critical to maximize the chances of success from a project’s start. For cell therapy development, where even small errors can make a big difference, it’s even more important.
{iframe}https://www.lifescienceleader.com/doc/implementing-gmp-for-early-phase-development-with-cartesian-therapeutics-co-founder-and-ceo-dr-murat-kalayoglu-0001{/iframe}